SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a massive parabolic rally driven by an extremely low float, intense short-squeeze dynamics, and significant speculation regarding its pivot from cannabis to telecommunications infrastructure in Mexico. The community is heavily focused on the high cost-to-borrow rates and the potential for a continued squeeze, leading to heated debates between bullish traders capitalizing on the momentum and skeptical observers warning of potential dilution and volatility.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is facing intense community backlash following the announcement of an 80 million dollar public offering of common stock and pre-funded warrants. Investors are expressing significant frustration over the resulting dilution, concerns regarding potential future reverse splits, and deep dissatisfaction with the company's capital management and leadership performance.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing extreme volatility and heavy volume as traders react to a recent preclinical milestone payment and an upcoming R&D presentation, while others express deep skepticism regarding the company's long-term performance and potential reverse split. The community is sharply divided, with bulls pointing to fundamental technology developments and Big Pharma partnerships, while bears highlight persistent dilution, management concerns, and a downward trend in share price.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors monitor the company's Q1 performance, characterized by significant revenue and EPS beats alongside robust user growth. The community is actively debating the stock's future trajectory, with some optimistic about its potential for a squeeze and long-term monetization, while others remain cautious regarding potential post-earnings volatility and broader software sector pressures.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox stock is currently reeling after a sharp post-earnings selloff, driven by lowered guidance, engagement concerns, and ongoing scrutiny over platform safety and user growth deceleration. While some community members view the dip as an attractive long-term entry point given the company's strong FCF and active user base, others remain skeptical, citing persistent profitability issues and potential regulatory risks.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is attracting significant community attention as investors debate its long-term potential following a strong earnings report that featured a 50% year-over-year revenue increase. While some participants express frustration with recent price volatility and bearish sentiment, many others are focused on the company's aggressive R&D spending and the successful adoption of its AI-driven platform as key catalysts for future growth.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending as investors debate the potential of its DePin infrastructure versus persistent concerns regarding price volatility and a lack of major news. The community remains deeply divided, with some actively accumulating positions during pullbacks in anticipation of a breakthrough, while others express frustration over stagnant price action and past unfulfilled expectations.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently surging on the strength of back-to-back mission successes and an aggressive launch cadence, with the community closely tracking its growing role in defense contracts and space infrastructure. Investors are highly optimistic about the stock's potential for triple-digit growth, driven by institutional confidence, anticipation of upcoming earnings, and the company's status as a key infrastructure player alongside SpaceX.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating buzz through aggressive social media cross-promotion with various other memecoins, sparking intense community debate between optimistic traders betting on rapid price momentum and skeptics questioning the token's long-term legitimacy.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing increased community interest and bullish sentiment following the release of positive Phase 4 study data demonstrating that Nuvaxovid offers statistically significant better tolerability than competing mRNA vaccines. Investors are actively discussing this development as a key catalyst for potential future partnerships and are closely monitoring the upcoming Sanofi earnings call for updates on the high-stakes COVID-Influenza Combination (CIC) vaccine program.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5%  - Should You Sell?

Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - What's Next...

Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat

Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High Following Earnings Beat...

Design Therapeutics Q1 Earnings Call Highlights

Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich's ataxia (FA), emphasizing that its ongoing RESTORE-FA multiple ascending dose study is intended to determine whether the therapy can meaningfully increase endogenous frataxin levels and help define a p...

Design Therapeutics (NASDAQ:DSGN) Posts Earnings Results, Beats Expectations By $0.07 EPS

Design Therapeutics (NASDAQ:DSGN - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.36) by...

Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week High - Still a Buy?

Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High - What's Next...

Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - Should You Buy?

Design Therapeutics (NASDAQ:DSGN) Hits New 52-Week High - Should You Buy...

Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat.com...

Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year High - What's Next?

Design Therapeutics (NASDAQ:DSGN) Hits New 12-Month High - Here's What Happened...

Design Therapeutics (NASDAQ:DSGN) Trading Up 6.8%  - Still a Buy?

Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.8% - Should You Buy...

Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - Here's What Happened

Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - What's Next...

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Current Price	$13.60
Prev Close	$15.79
Open	$15.76
Dividend Yield	0.00%
50-Day Moving Average	$11.38
Beta	1.65
Avg. Volume	282,414.55
PE Ratio	-11.40

52-Week High	$17.25
52-Week Low	$3.11
Market Capitalization	$986.2M
EPS (Annual)	-$1.22
Price to Book	3.89
Revenue Per Employee	$0.00

DSGN
Design Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DSGN News

DSGNDesign Therapeutics Inc